Wall Street analysts expect that Audentes Therapeutics Inc (NASDAQ:BOLD) will report ($0.92) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Audentes Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.84) and the lowest estimate coming in at ($1.08). Audentes Therapeutics reported earnings of ($0.91) per share in the same quarter last year, which would indicate a negative year over year growth rate of 1.1%. The firm is scheduled to issue its next earnings results on Thursday, March 8th.
On average, analysts expect that Audentes Therapeutics will report full-year earnings of ($3.50) per share for the current fiscal year, with EPS estimates ranging from ($3.69) to ($3.42). For the next fiscal year, analysts expect that the business will report earnings of ($3.70) per share, with EPS estimates ranging from ($5.31) to ($3.20). Zacks’ EPS averages are an average based on a survey of analysts that follow Audentes Therapeutics.
BOLD has been the subject of a number of research reports. Leerink Swann reiterated an “outperform” rating and set a $29.00 price objective (up previously from $22.00) on shares of Audentes Therapeutics in a research report on Wednesday, November 15th. HC Wainwright set a $37.00 price objective on Audentes Therapeutics and gave the company a “buy” rating in a research report on Thursday, January 11th. Zacks Investment Research upgraded Audentes Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 9th. Mizuho initiated coverage on Audentes Therapeutics in a research report on Monday. They set a “neutral” rating and a $26.00 price objective for the company. Finally, BidaskClub cut Audentes Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 6th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Audentes Therapeutics has a consensus rating of “Buy” and an average target price of $34.00.
A number of institutional investors and hedge funds have recently modified their holdings of BOLD. Vanguard Group Inc. increased its position in Audentes Therapeutics by 130.3% in the second quarter. Vanguard Group Inc. now owns 678,412 shares of the biotechnology company’s stock worth $12,978,000 after buying an additional 383,837 shares in the last quarter. Farallon Capital Management LLC purchased a new stake in Audentes Therapeutics in the fourth quarter worth about $9,989,000. Citadel Advisors LLC increased its position in Audentes Therapeutics by 206.2% in the fourth quarter. Citadel Advisors LLC now owns 339,588 shares of the biotechnology company’s stock worth $10,612,000 after buying an additional 228,667 shares in the last quarter. Artal Group S.A. purchased a new stake in shares of Audentes Therapeutics during the third quarter worth about $5,602,000. Finally, BlackRock Inc. grew its position in shares of Audentes Therapeutics by 13.2% during the fourth quarter. BlackRock Inc. now owns 1,358,498 shares of the biotechnology company’s stock worth $42,452,000 after purchasing an additional 158,576 shares in the last quarter. Institutional investors and hedge funds own 64.94% of the company’s stock.
Audentes Therapeutics (NASDAQ BOLD) traded up $0.81 during trading on Thursday, reaching $32.82. The company had a trading volume of 195,000 shares, compared to its average volume of 533,067. The stock has a market capitalization of $1,163.45, a PE ratio of -9.40 and a beta of 0.41. Audentes Therapeutics has a 12 month low of $13.90 and a 12 month high of $41.80.
About Audentes Therapeutics
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.